Wall Street brokerages expect Mylan NV (NASDAQ:MYL) to announce $1.14 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Mylan’s earnings, with the lowest EPS estimate coming in at $1.09 and the highest estimate coming in at $1.17. Mylan reported earnings per share of $1.25 during the same quarter last year, which suggests a negative year over year growth rate of 8.8%. The company is scheduled to report its next quarterly earnings results before the market opens on Tuesday, November 5th.
On average, analysts expect that Mylan will report full year earnings of $4.26 per share for the current fiscal year, with EPS estimates ranging from $4.10 to $4.44. For the next year, analysts anticipate that the company will post earnings of $4.47 per share, with EPS estimates ranging from $4.30 to $4.65. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Mylan.
Mylan (NASDAQ:MYL) last issued its quarterly earnings data on Monday, July 29th. The company reported $1.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.95 by $0.08. The business had revenue of $2.85 billion for the quarter, compared to the consensus estimate of $2.82 billion. Mylan had a return on equity of 18.93% and a net margin of 0.30%. The firm’s revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.07 EPS.
In related news, Director Richard A. Mark acquired 4,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was bought at an average price of $20.97 per share, for a total transaction of $83,880.00. Following the acquisition, the director now directly owns 4,000 shares of the company’s stock, valued at $83,880. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert J. Coury acquired 49,859 shares of the firm’s stock in a transaction dated Friday, August 2nd. The stock was bought at an average price of $20.06 per share, with a total value of $1,000,171.54. Following the acquisition, the director now directly owns 947,194 shares in the company, valued at $19,000,711.64. The disclosure for this purchase can be found here. Insiders bought a total of 83,859 shares of company stock valued at $1,628,752 in the last 90 days. 0.81% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Advisor Group Inc. grew its holdings in shares of Mylan by 347.3% in the 2nd quarter. Advisor Group Inc. now owns 45,688 shares of the company’s stock valued at $870,000 after acquiring an additional 35,474 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new position in shares of Mylan in the 2nd quarter valued at about $804,000. Voloridge Investment Management LLC bought a new position in shares of Mylan in the 2nd quarter valued at about $4,064,000. ARGA Investment Management LP grew its holdings in shares of Mylan by 75.5% in the 2nd quarter. ARGA Investment Management LP now owns 182,898 shares of the company’s stock valued at $3,482,000 after acquiring an additional 78,698 shares in the last quarter. Finally, Signaturefd LLC grew its holdings in Mylan by 271.8% during the second quarter. Signaturefd LLC now owns 3,376 shares of the company’s stock worth $64,000 after purchasing an additional 2,468 shares during the period. Institutional investors own 84.75% of the company’s stock.
Shares of Mylan stock opened at $18.25 on Tuesday. The company has a market capitalization of $9.56 billion, a PE ratio of 4.21, a PEG ratio of 0.88 and a beta of 1.80. Mylan has a 12 month low of $16.63 and a 12 month high of $37.56. The company has a current ratio of 1.37, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15. The stock’s fifty day simple moving average is $19.74 and its 200 day simple moving average is $20.36.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
See Also: Dow Jones Industrial Average (DJIA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.